Gastrointestinal adverse events, including diarrhoea, nausea, and vomiting, were consistently the most common side effects reported across all dose groups in the phase 2 trial
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications used primarily for type 2 diabetes management and, in some formulations, for chronic weight management
Collectively they found that a truncated form of GLP-1 produced by gut cells was able to bind a G-protein coupled receptor (GPCR) expressed on pancreatic islet cells and in other tissues
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
He said: "Overall, I've been surprised how willing people are to inject
Behavioral support improves eating and activity routines between visits